MACPAC’S Mission is to Ensure Access. NOT DENY it to Our Most Vulnerable!
RAAP Set to Fight MACPAC Efforts to Restrict Access to Rare Medicines in Medicaid. On Friday, January 27th, the Medicaid and CHIP Payment and Access Commission (MACPAC) voted to recommend that Congress permit states to restrict and delay access to therapies approved under the accelerated approval pathway. The U.S. Congress already mandated, as part of the Medicaid rebate agreement, that patients must have access to therapies at FDA approval. This includes medications under the accelerated approval pathway.
